In July, the Pharmaceutical Executive published its latest annual ranking of the top 50 biopharma companies according to prescription drug sales in 2018. Once again, Pfizer led the ranking with $45 billion in sales spurred by its top sellers Prevnar 13, Lyrica and Enbrel. Sales of the breast cancer drug Ibrance, which was approved for use in males in April of 2018, also bolstered Pfizer's sales, according to the Pharmaceutical Exec. Pfizer has been in the top of the ranking for the fourth consecutive year.
Swiss company Roche was listed second in prescription sales but spent the most on research and development compared to its competitors. The Basel-based enterprise paid almost $10 billion for R&A. The company climbed to the runner-up position from third place. Herceptine was Roche's top-selling prescription drug, despite the cancer drug's patent has expired. This led to falling sales of Herceptine, as the competition was moving in with their versions of the drug.
Swiss company Roche was listed second in prescription sales but spent the most on research and development compared to its competitors. The Basel-based enterprise paid almost $10 billion for R&A. The company climbed to the runner-up position from third place. Herceptine was Roche's top-selling prescription drug, despite the cancer drug's patent has expired. This led to falling sales of Herceptine, as the competition was moving in with their versions of the drug.
No comments:
Post a Comment